Scarica l'app Stockscreener
4.16
4.00%
0.16
Dopo l'orario di chiusura:
4.33
0.17
+4.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.00
Aprire:
$4.06
Volume 24 ore:
167.07K
Relative Volume:
0.27
Capitalizzazione di mercato:
$266.49M
Reddito:
-
Utile/perdita netta:
$-45.08M
Rapporto P/E:
-5.6986
EPS:
-0.73
Flusso di cassa netto:
$-33.68M
1 W Prestazione:
+10.93%
1M Prestazione:
+42.96%
6M Prestazione:
+173.68%
1 anno Prestazione:
+71.19%
Intervallo 1D:
$4.05
$4.1896
Intervallo di 1 settimana:
$3.67
$4.1896
Portata 52W:
$0.726
$4.41
Galectin Therapeutics Inc Stock (GALT) Company Profile
Nome
Galectin Therapeutics Inc
Settore
Industria
Telefono
678-620-3186
Indirizzo
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Confronta GALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
4.16 | 249.84M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
387.18 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
587.65 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
451.20 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
708.09 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.91 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Ripresa | H.C. Wainwright | Buy |
| 2020-08-13 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-13 | Iniziato | B. Riley FBR | Buy |
| 2017-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-19 | Iniziato | ROTH Capital | Buy |
| 2017-03-30 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | Downgrade | ROTH Capital | Buy → Sell |
| 2016-03-28 | Ripresa | H.C. Wainwright | Buy |
| 2015-09-21 | Iniziato | H.C. Wainwright | Buy |
| 2014-08-01 | Downgrade | Aegis Capital | Buy → Hold |
| 2014-07-30 | Reiterato | MLV & Co | Buy |
| 2014-07-29 | Reiterato | MLV & Co | Buy |
| 2014-04-02 | Reiterato | MLV & Co | Buy |
| 2014-02-10 | Reiterato | Aegis Capital | Buy |
| 2014-01-09 | Reiterato | Aegis Capital | Buy |
| 2013-12-03 | Iniziato | MLV & Co | Buy |
| 2013-08-19 | Reiterato | Aegis Capital | Buy |
Mostra tutto
Galectin Therapeutics Inc Borsa (GALT) Ultime notizie
What’s next for Galectin Therapeutics Inc. stock priceEarnings Overview Summary & Weekly Top Gainers Trade List - Newser
Will Galectin Therapeutics Inc. benefit from macro trendsJuly 2025 Breakouts & Expert Verified Stock Movement Alerts - Newser
Galectin Therapeutics Inc. Included in Top Momentum ScanJuly 2025 Drop Watch & Low Drawdown Investment Strategies - Newser
Can Galectin Therapeutics Inc. recover in the next quarterTrade Signal Summary & Intraday High Probability Alerts - Newser
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving AverageTime to Sell? - MarketBeat
Comparing Galectin Therapeutics Inc. in custom built stock radarsJuly 2025 Setups & High Accuracy Investment Signals - Newser
Will Galectin Therapeutics Inc. stock recover after recent dropMarket Risk Analysis & Free Real-Time Market Sentiment Alerts - Newser
Is Galectin Therapeutics Inc. trending in predictive chart models2025 Technical Patterns & Weekly Momentum Picks - Newser
Galectin Therapeutics (NASDAQ:GALT) Posts Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
Will Galectin Therapeutics Inc. stock go up soonPortfolio Return Report & Technical Entry and Exit Tips - Newser
Galectin Therapeutics (NASDAQ:GALT) Earns Buy Rating from HC Wainwright - MarketBeat
Galectin Therapeutics : Corporate Presentation, August 2025 - MarketScreener
Is Galectin Therapeutics Inc. a candidate for recovery play2025 Pullback Review & Expert Curated Trade Ideas - Newser
Galectin Therapeutics Inc. stock retracement – recovery analysisQuarterly Risk Review & Technical Entry and Exit Tips - Newser
How Galectin Therapeutics Inc. stock performs during market volatilityTrade Analysis Summary & Daily Oversold Stock Bounce Ideas - Newser
Technical analysis overview for Galectin Therapeutics Inc. stockJuly 2025 Intraday Action & Growth Oriented Trade Recommendations - Newser
Galectin Therapeutics Inc. stock volume spike explained2025 Growth vs Value & Technical Pattern Recognition Alerts - Newser
HC Wainwright Has Optimistic Outlook of GALT Q3 Earnings - MarketBeat
Quantitative breakdown of Galectin Therapeutics Inc. recent moveMarket Volume Report & Accurate Intraday Trade Tips - Newser
Price momentum metrics for Galectin Therapeutics Inc. explainedTreasury Yields & Fast Gaining Stock Reports - Newser
HC Wainwright Brokers Increase Earnings Estimates for GALT - Defense World
What data driven models say about Galectin Therapeutics Inc.’s futureQuarterly Trade Report & Precise Buy Zone Tips - Newser
Backtesting results for Galectin Therapeutics Inc. trading strategies2025 Key Highlights & Technical Pattern Alert System - Newser
Is it time to cut losses on Galectin Therapeutics Inc.Market Growth Summary & Community Consensus Trade Signals - Newser
What recovery options are there for Galectin Therapeutics Inc.July 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - Newser
Galectin Therapeutics Reports Reduced Losses in Q2 2025 - MSN
Live market analysis of Galectin Therapeutics Inc.Gap Up & Safe Entry Trade Signal Reports - Newser
Signal strength of Galectin Therapeutics Inc. stock in tech scannersJuly 2025 Summary & Scalable Portfolio Growth Methods - Newser
Is Galectin Therapeutics Inc. a turnaround story2025 Biggest Moves & Community Verified Trade Alerts - thegnnews.com
Does Galectin Therapeutics Inc. qualify in momentum factor screeningWeekly Market Report & Safe Entry Point Identification - Newser
Does Galectin Therapeutics Inc. show high probability of reboundEarnings Risk Report & Consistent Growth Equity Picks - Newser
Top Risks to Consider Before Buying Galectin Therapeutics Inc. StockJuly 2025 Momentum & AI Enhanced Execution Alerts - Newser
Earnings visualization tools for Galectin Therapeutics Inc.Weekly Trend Report & Fast Entry High Yield Tips - Newser
What makes Galectin Therapeutics Inc. stock price move sharply2025 Trading Volume Trends & Precise Trade Entry Recommendations - Newser
Combining price and volume data for Galectin Therapeutics Inc.Trade Volume Report & Capital Protection Trade Alerts - Newser
Predicting Galectin Therapeutics Inc. trend using moving averagesJuly 2025 PostEarnings & Short-Term Swing Trade Alerts - Newser
why galectin therapeutics inc. stock attracts strong analyst attentionQuarterly Trade Summary & Community Consensus Trade Alerts - Newser
Galectin Therapeutics Inc Azioni (GALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Galectin Therapeutics Inc Azioni (GALT) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| FREEMAN KEVIN D | Director |
Jul 17 '25 |
Buy |
2.90 |
5,000 |
14,495 |
49,769 |
| CZIRR JAMES C | 10% Owner |
Jun 06 '25 |
Option Exercise |
2.16 |
323,125 |
699,344 |
1,045,541 |
| Shlevin Harold H. | Director |
Dec 30 '24 |
Buy |
1.16 |
6,500 |
7,540 |
15,206 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
40,000 |
| Jamil Khurram | Chief Medical Officer |
Dec 23 '24 |
Sale |
0.88 |
13,654 |
12,044 |
26,346 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Option Exercise |
0.00 |
56,000 |
0 |
953,012 |
| LEWIS JOEL | President and CEO |
Dec 23 '24 |
Sale |
0.89 |
56,000 |
49,610 |
897,012 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Option Exercise |
0.00 |
40,000 |
0 |
47,614 |
| CALLICUTT JACK W | Chief Financial Officer |
Dec 23 '24 |
Sale |
0.89 |
40,000 |
35,492 |
7,614 |
| Zordani Richard A. Jr. | Director |
Dec 24 '24 |
Buy |
0.82 |
10,000 |
8,164 |
42,083 |
0.95%
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):